Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in early-stage MSA completed in November ...

New biomarker tests can enable early diagnosis and prompt treatment of symptoms associated with synucleinopathies, according ...

Dancing the Blues Away' Seen in Brain Imaging in People With Parkinson's Disease, New Study Finds Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the ...

Dancing the Blues Away' Seen in Brain Imaging in People With Parkinson's Disease, New Study Finds Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the ...

Yulan Xiong, associate professor of neuroscience at UConn Health, and her team have discovered one more piece of the puzzle of the genetic causes of Parkinson's Disease, paving the way for new ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

ONO-2808 is under clinical development by Ono Pharmaceutical and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). According to GlobalData, ...

Researchers have discovered a new biomarker for Parkinson’s that could be used to identify people at risk of the disease and profoundly change the way it is treated. The assay for a particular ...

Welcome to IIE MSA, the largest private higher education campus in SA, located in the heart of Ruimsig, Johannesburg. This is your gateway to a future filled with possibilities, where academic ...

37 new cases of Parkinson's disease are diagnosed every single day - yet we still don't know the cause, and there is no cure. Even more concerning, the number of people living with the disease is ...